Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Komzifti (ziftomenib) Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.765

    Ziftomenib (Komzifti) coverage

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.765 alerts

    Get alerted when Policy CP.PHAR.765 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for ziftomenib (Komzifti) for treatment of adult patients with relapsed or refractory NPM1‑mutated acute myeloid leukemia across QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyZiftomenib (Komzifti) coverage
    Policy CodePolicy CP.PHAR.765
    Change TypeNo material change
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) supporting that member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    600 mg/dayMaximum AML dose
    200 mgCapsule strength
    ≥ 18Minimum age
    Differentiation syndrome

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Boxed warning

    Coverage Criteria

    inv-03: Other Diagnoses/Indications

    Other indications: 1. If the drug has had a label change within the last 6 months that is not yet reflected in this policy, follow the applicable formulary/no-coverage or non-formulary policy for the relevant line of business (see policy references); OR 2. If the requested use is not specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (commercial, health insurance marketplace, or Medicaid).

    See referenced policies: CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16, CP.CPA.09, HIM.PA.154, CP.PMN.53.

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or other approved evidence of coverage documents.

    Uses of Komzifti for non‑FDA approved indications that lack adequate supporting evidence per the referenced off‑label policies are considered not medically necessary and will not be authorized.

    Initial Therapy (AML) Requirements

    Continuation Therapy (AML) Requirements

    Coding and Dose Limits

    Dose limits
    Minimum dose for coverage200 mg per day
    Maximum dose for coverage600 mg per day
    Approval condition for higher dosesDose >600 mg/day allowed only if supported by practice guidelines or peer‑reviewed literature with prescriber submission of evidence

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required; 12-month approvals

    Prior authorization is required for Komzifti (ziftomenib). When the member meets the initial or continued therapy criteria, approvals are issued for a duration of 12 months.

    Step Therapy

    Preferred agent requirement — use ziftomenib when available

    For Komzifti requests, the prescriber must use ziftomenib when it is available unless the member has a contraindication or experiences clinically significant adverse effects or intolerance.

    Documentation Required

    Submit supportive clinical documentation

    Step Therapy / Substitution Rules

    StepRequirement
    1Prescriber must use ziftomenib when available for Komzifti requests unless contraindicated or clinically significant adverse effects occur.

    Quantity Limits

    Komzifti (ziftomenib) — Quantity limits
    Maximum daily doseUp to 600 mg/day (3 capsules of 200 mg)
    Available capsule strength200 mg capsule
    Typical AML dosing regimenAML dosing regimen listed as 600 mg PO QD

    Site of Care

    Note

    Site of care: none specified

    No site-of-care restrictions are specified in this policy.

    Background

    Ziftomenib (Komzifti) is a menin inhibitor indicated in this policy context for specific treatment of acute myeloid leukemia. Requests for indications outside the FDA‑approved labeling are subject to review and must include documentation demonstrating efficacy and safety per the off‑label use policies cited elsewhere in this document.

    Definitions

    Definition: NPM1
    TermNPM1
    Definitionnucleophosmin 1
    ContextUsed in policy to define mutation status required for coverage in AML
    Definition: AML
    TermAML
    Definitionacute myeloid leukemia
    ContextIndication: relapsed or refractory AML with susceptible NPM1 mutation (coverage criteria)
    Policy Summary
    PayerQualChoice
    PolicyZiftomenib (Komzifti) coverage
    Policy CodePolicy CP.PHAR.765
    Change TypeNo material change
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) supporting that member meets all approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy (AML) RequirementsContinuation Therapy (AML) RequirementsCoding and Dose LimitsProvider Actions and RequirementsStep Therapy / Substitution RulesQuantity LimitsSite of CareBackgroundDefinitions

    Providers must submit supporting clinical documentation (such as office chart notes, laboratory results, or other clinical information) showing the member meets all applicable approval criteria.

    • Examples: office chart notes, lab results, other clinical information
    Denial Risk

    Non‑FDA indications lacking sufficient evidence may be denied

    Requests for non–FDA approved indications that are not addressed in this policy may be denied if there is insufficient documentation of efficacy and safety per the referenced off‑label use policies.

    • Refer to off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), CP.PMN.53 (Medicaid).